Evidence map›Paper›PMID 38956268›Full record

ArticleCommunications medicine2024

High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance.

Yu-Hwa Huang, Charles H Yoon, Amit Gandhi, Thomas Hanley, Carlos Castrillon, Yasuyuki Kondo, Xi Lin, Walter Kim, Chao Yang, Amine Driouchi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Mechanism and function of CEACAM1 splice isoforms.European journal of clinical investigation · 2024
    Review
  5. Review
  6. Structural aspects of CEACAM1 interactions.European journal of clinical investigation · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yu-Hwa Huang *Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. yhuang17@bwh.harvard.edu.
Charles H Yoon *Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Amit GandhiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0654-1097
Thomas HanleyDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carlos CastrillonProgram in Cellular and Molecular Medicine, Children's Hospital Medical Center, Harvard Medical School, Boston, MA, USA.
Yasuyuki KondoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xi LinDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Walter KimDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Chao YangDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Amine DriouchiInstitute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
Michael CarrollProgram in Cellular and Molecular Medicine, Children's Hospital Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3213-4295
Scott D Gray-OwenDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1477-3616
Duane R WesemannDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6690-944X
Charles G DrakeHerbert Irving Comprehensive Cancer Center, Columbia University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-9610-3677
Monica M BertagnolliDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nicole BeaucheminRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Richard S BlumbergDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. rblumberg@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-9704-248X

Funding

Regulation of Mucosal LymphocytesR01DK051362 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Richard S Blumberg, Yu-Hwa Huang Blumberg · 1997 to 2026
$13.5M
Evolution of autoreactive GC and epitope spreading in lupusR01AR074105 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI Michael Craig Carroll · 2018 to 2026
$4.2M
NIAMS NIH HHS R01 AR074105NIDDK NIH HHS R01 DK051362
6 · The paper itself

Abstract

backgroundHuman carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is an inhibitory cell surface protein that functions through homophilic and heterophilic ligand binding. Its expression on immune cells in human tumors is poorly understood.

methodsAn antibody that distinguishes human CEACAM1 from other highly related CEACAM family members was labeled with

resultsCEACAM1 is absent or at low levels on healthy circulating immune cells but is increased on immune cells in peripheral blood and tumors of melanoma patients. The majority of circulating PD1-positive NK cells, innate T cells, B cells, monocytic cells, dendritic cells, and CD4

conclusionsTo the best of our knowledge, this work represents the first comprehensive atlas of CEACAM1 expression on immune cells in a human tumor and reveals an important correlation with treatment-resistant disease. These studies suggest that agents targeting CEACAM1 may represent appropriate partners for PD1-related pathway therapies.

Identifiers

PMID38956268
PMCPMC11219841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.